Advertisement
Canada markets open in 3 hours 20 minutes
  • S&P/TSX

    21,871.96
    +64.59 (+0.30%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CAD/USD

    0.7296
    -0.0005 (-0.07%)
     
  • CRUDE OIL

    81.93
    +0.03 (+0.04%)
     
  • Bitcoin CAD

    90,703.04
    +245.69 (+0.27%)
     
  • CMC Crypto 200

    1,420.16
    +5.40 (+0.38%)
     
  • GOLD FUTURES

    2,309.10
    -37.30 (-1.59%)
     
  • RUSSELL 2000

    1,967.47
    +19.82 (+1.02%)
     
  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     
  • NASDAQ futures

    17,377.00
    +27.00 (+0.16%)
     
  • VOLATILITY

    16.75
    -0.19 (-1.12%)
     
  • FTSE

    8,048.56
    +24.69 (+0.31%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • CAD/EUR

    0.6841
    -0.0009 (-0.13%)
     

Aptamer Group First Half 2023 Earnings: UK£0.038 loss per share (vs UK£0.018 loss in 1H 2022)

Aptamer Group (LON:APTA) First Half 2023 Results

Key Financial Results

  • Revenue: UK£1.02m (down 26% from 1H 2022).

  • Net loss: UK£2.63m (loss widened by 139% from 1H 2022).

  • UK£0.038 loss per share (further deteriorated from UK£0.018 loss in 1H 2022).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Aptamer Group Earnings Insights

Looking ahead, revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom.

Performance of the British Biotechs industry.

The company's shares are down 23% from a week ago.

Risk Analysis

You should learn about the 5 warning signs we've spotted with Aptamer Group (including 3 which are a bit concerning).

ADVERTISEMENT

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here